Healthcare >> CEO Interviews >> July 28, 2003
MARTIN M. MCGLYNN joined StemCells, Inc., in January 2001 as its
President and Chief Executive Officer and was elected to its Board of
Directors on February 6, 2001. Mr. McGlynn has spent several decades in
the life sciences industry in Europe, Canada and the United States. He
began his career with Becton Dickinson Ireland, Ltd., and spent eight
years in manufacturing operations. He joined Abbott Labs in 1977 where
he held positions as General Manager, Abbott Ireland Ltd., President and
General Manager of Abbott Canada Ltd. and Vice President of Abbott
International Ltd. In 1990, he joined the BOC Group as President of
Anaquest, Inc., a global leader in anesthesia and acute care
pharmaceuticals headquartered in New Jersey. Mr. McGlynn joined the
biotech industry in 1994 when he became President and CEO of Pharmadigm,
Inc., a privately held, venture capital backed startup company engaged
in the research and development of a new class of anti-inflammatory
agents. Mr. McGlynn is a native of Dublin, Ireland. He holds a Bachelor
of Commerce degree from University College Dublin. He is a former member
of the Board of Directors of the Confederation of Irish Industries (CII)
and the Pharmaceutical Manufacturers Association of Canada (PMAC). Profile
Mr. McGlynn: StemCells, Inc. (STEM) is a publicly traded company quoted
on the NASDAQ. It was originally founded in 1995 by three icons
